{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"29.1","upperLimit":"32.0","value":"30.5"},{"groupId":"OG001","lowerLimit":"19.37","upperLimit":"23.70","value":"21.4"},{"groupId":"OG002","lowerLimit":"22.02","upperLimit":"25.87","value":"23.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"53"},{"groupId":"OG002","value":"30"}],"units":"Participants"}],"description":"Blood samples from participants were collected for population pharmacokinetic analysis including the apparent base clearance (CL/F) following oral dosing of dabrafenib. Concentrations of dabrafenib was determined in plasma samples using the currently approved analytical methodology.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with or without prior systemic anti-cancer therapy received Dabrafenib 150 mg BID until disease progression, death, or unacceptable adverse event(s) (AEs) or investigator discretion to discontinue or decision to crossover from monotherapy to combination therapy.","id":"OG000","title":"Cohort A (Dabrafenib Monotherapy): Dabrafenib Monotherapy 150mg BID"},{"description":"Participants who had received 1-3 prior lines of systemic anti-cancer therapies for advanced stage/metastatic disease received Dabrafenib 150 mg BID and Trametinib 2 mg once daily (OD). Treatment continued until disease progression, death, or unacceptable AEs or investigator discretion to discontinue.","id":"OG001","title":"Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD"},{"description":"Participants who had not received any prior systemic anti-cancer for metastatic disease therapies were given Dabrafenib 150 mg BID and Trametinib 2 mg OD. Treatment continued until disease progression, death, or unacceptable AEs or at investigator discretion to discontinue.","id":"OG002","title":"Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All subjects who received at least one dose of dabrafenib in the Cohort A (Dabrafenib Monotherapy) and in the doublets combination (Dabrafenib + Trametinib) Cohort B and C and provided an evaluable PK profile.","reportingStatus":"POSTED","timeFrame":"Week 3, Week 6, Week 12 and Week 18","title":"Apparent Clearance (CL/F) of Dabrafenib","type":"SECONDARY","unitOfMeasure":"Liter/hour (L/hr)"}